-
1
-
-
33847281230
-
Rhabdomyosarcoma and the undifferentiate.d sarcomas
-
Pizzo PA Poplack DG editors 5th edition. Lippincott Williams & Wilkins, Philadelphia, PA;
-
Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA, Poplack DG, editors, Principles and practice of pediatric oncology. 5th edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2006. p. 971-1001
-
(2006)
Principles and Practice of Pediatric Oncology
, pp. 971-1001
-
-
Wexler, L.H.1
Meyer, W.H.2
Helman, L.J.3
-
2
-
-
33947509741
-
Nonrhabdomyosarcomatous soft tissue sarcomas
-
PA Poplack DC editors 5th edition Lippincott Williams & Wilkins, Philadelphia;
-
Okcu MF, Hicks J, Merchant TE, et al. Nonrhabdomyosarcomatous soft tissue sarcomas. In: Pizzo PA, Poplack DC, editors, Principles and practice of pediatric oncology. 5th edition. Lippincott Williams & Wilkins, Philadelphia; 2006. p. 1033-73
-
(2006)
Principles and Practice of Pediatric Oncology
, pp. 1033-1073
-
-
Okcu, M.F.1
Hicks, J.2
Merchant, T.E.3
-
6
-
-
17544367893
-
Current chemotherapeutic strategies for rhabdomyosarcoma
-
DOI 10.1586/14737140.5.2.283
-
Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev Anticancer Ther 2005;5:283-94 (Pubitemid 40553093)
-
(2005)
Expert Review of Anticancer Therapy
, vol.5
, Issue.2
, pp. 283-294
-
-
Ferrari, A.1
Casanova, M.2
-
7
-
-
17544363935
-
New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas
-
DOI 10.1586/14737140.5.2.307
-
Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2005;5:307-18 (Pubitemid 40553095)
-
(2005)
Expert Review of Anticancer Therapy
, vol.5
, Issue.2
, pp. 307-318
-
-
Ferrari, A.1
Casanova, M.2
-
8
-
-
0032794460
-
Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: An analysis of 121 patients treated at St jude childrens research hospital
-
Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol 1999;17:3697-705
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 3697-705
-
-
Spunt, S.L.1
Poquette, C.A.2
Hurt, Y.S.3
-
9
-
-
23044483559
-
Adult-type soft tissue sarcomas in pediatric-age patients: Experience at the Istituto Nazionale Tumori in Milan
-
DOI 10.1200/JCO.2005.02.053
-
Ferrari A, Casanova M, Meazza C, et al. Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 2005;23:4021-30 (Pubitemid 46211306)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4021-4030
-
-
Ferrari, A.1
Casanova, M.2
Collini, P.3
Meazza, C.4
Luksch, R.5
Massimino, M.6
Cefalo, G.7
Terenziani, M.8
Spreafico, F.9
Catania, S.10
Gandola, L.11
Gronchi, A.12
Mariani, L.13
Fossati-Bellani, F.14
-
10
-
-
13344286225
-
Treatment for childhood rhabdomyosarcoma: The cost of cure
-
DOI 10.1016/S1470-2045(05)01733-X, PII S147020450501733X
-
Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 2005;6:77-84 (Pubitemid 40197701)
-
(2005)
Lancet Oncology
, vol.6
, Issue.2
, pp. 77-84
-
-
Stevens, M.C.G.1
-
11
-
-
0035154736
-
Treatment of orbital rhabdomyosarcoma: Survival and late effects of treatment - Results of an international workshop
-
Oberlin O, Rey A, Anderson J, et al.Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment - results of an international workshop. J Clin Oncol 2001;19:197-204 (Pubitemid 32063497)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.1
, pp. 197-204
-
-
Oberlin, O.1
Rey, A.2
Anderson, J.3
Carli, M.4
Raney, R.B.5
Treuner, J.6
Stevens, M.C.G.7
-
12
-
-
62449192357
-
Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: Results from international society of pediatric oncology studies MMT 89 and 95
-
Defachelles AS, Rey A, Oberlin O, et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J Clin Oncol 2009;27:1310-5
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 1310-1315
-
-
Defachelles, A.S.1
Rey, A.2
Oberlin, O.3
-
14
-
-
0023889668
-
Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma
-
Carli M, Pastore G, Perilongo G, et al. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 1988;6:654-8
-
(1988)
J. Clin. Oncol.
, vol.6
, pp. 654-658
-
-
Carli, M.1
Pastore, G.2
Perilongo, G.3
-
15
-
-
0035876634
-
Intergroup Rhabdomyosarcoma Study-IV: Results for patients with nonmetastatic disease
-
Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102 (Pubitemid 32567502)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.12
, pp. 3091-3102
-
-
Crist, W.M.1
Anderson, J.R.2
Meza, J.L.3
Fryer, C.4
Raney, R.B.5
Ruymann, F.B.6
Breneman, J.7
Qualman, S.J.8
Wiener, E.9
Wharam, M.10
Lobe, T.11
Webber, B.12
Maurer, H.M.13
Donaldson, S.S.14
-
16
-
-
4644335909
-
Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: A report from the soft tissue sarcoma committee of the children's oncology group
-
DOI 10.1158/1078-0432.CCR-04-0654
-
Spunt SL, Smith LM, Ruymann FB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res 2004;10:6072-9 (Pubitemid 39287511)
-
(2004)
Clinical Cancer Research
, vol.10
, pp. 6072-6079
-
-
Spunt, S.L.1
Smith, L.M.2
Ruymann, F.B.3
Qualman, S.J.4
Donaldson, S.S.5
Rodeberg, D.A.6
Anderson, J.R.7
Crist, W.M.8
Link, M.P.9
-
17
-
-
38749137720
-
Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic disease
-
Bergeron C, Thiesse P, Rey A, et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 2008;44:427-31
-
(2008)
Eur. J. Cancer
, vol.44
, pp. 427-431
-
-
Bergeron, C.1
Thiesse, P.2
Rey, A.3
-
18
-
-
21044458873
-
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology-SIOP malignant mesenchymal tumor 89
-
DOI 10.1200/JCO.2005.08.130
-
Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology -SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618-28 (Pubitemid 46179450)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.12
, pp. 2618-2628
-
-
Stevens, M.C.G.1
Rey, A.2
Bouvet, N.3
Ellershaw, C.4
Flamant, F.5
Habrand, J.L.6
Marsden, H.B.7
Martelli, H.8
De Toledo, J.S.9
Spicer, R.D.10
Spooner, D.11
Terrier-Lacombe, M.J.12
Van Unnik, A.13
Oberlin, O.14
-
19
-
-
0028964049
-
The third Intergroup Rhabdomyosarcoma Study
-
Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30
-
(1995)
J. Clin. Oncol.
, vol.13
, pp. 610-630
-
-
Crist, W.1
Gehan, E.A.2
Ragab, A.H.3
-
20
-
-
0027534434
-
The Intergroup Rhabdomyosarcoma Studies come of age
-
Womer RB. The Intergroup Rhabdomyosarcoma Studies come of age. Cancer 1993;71:1719-21 (Pubitemid 23067384)
-
(1993)
Cancer
, vol.71
, Issue.5
, pp. 1719-1721
-
-
Womer, R.B.1
-
21
-
-
36849009613
-
Comparison of results of a pilot study of alternating vincristine/ doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: A report from the children's oncology group
-
DOI 10.1002/pbc.21093
-
Arndt CA, Hawkins DS, Meyer WH, et al. Comparison of results of a pilot study of alternating vincristine/ doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;50:33-6 (Pubitemid 350234262)
-
(2008)
Pediatric Blood and Cancer
, vol.50
, Issue.1
, pp. 33-36
-
-
Arndt, C.A.S.1
Hawkins, D.S.2
Meyer, W.H.3
Sencer, S.F.4
Neglia, J.P.5
Anderson, J.R.6
-
22
-
-
20144388870
-
The IVADo regimen - A pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: A pilot study on behalf of the European pediatric soft tissue sarcoma study group
-
DOI 10.1002/cncr.20928
-
Bisogno G, Ferrari A, Bergeron C, et al. The IVADo regimen - a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study on behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005;103:1719-24 (Pubitemid 40490034)
-
(2005)
Cancer
, vol.103
, Issue.8
, pp. 1719-1724
-
-
Bisogno, G.1
Ferrari, A.2
Bergeron, C.3
Scagnellato, A.4
Prete, A.5
Alaggio, R.6
Casanova, M.7
D'Angelo, P.8
Di Cataldo, A.9
Carli, M.10
-
23
-
-
33746821135
-
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group
-
DOI 10.1200/JCO.2005.01.9497
-
Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006;24:3415-22 (Pubitemid 46638898)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.21
, pp. 3415-3422
-
-
Lager, J.J.1
Lyden, E.R.2
Anderson, J.R.3
Pappo, A.S.4
Meyer, W.H.5
Breitfeld, P.P.6
-
24
-
-
0031939569
-
Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: A collaborative pediatric branch, national cancer institute, and children's cancer group study
-
Blaney SM, Needle MN, Gillespie A, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 1998;4:357-60 (Pubitemid 28122750)
-
(1998)
Clinical Cancer Research
, vol.4
, Issue.2
, pp. 357-360
-
-
Blaney, S.M.1
Needle, M.N.2
Gillespie, A.3
Sato, J.K.4
Reaman, G.H.5
Berg, S.L.6
Adamson, P.C.7
Krailo, M.D.8
Bleyer, W.A.9
Poplack, D.G.10
Balis, F.M.11
-
25
-
-
0031759531
-
Topotecan in pediatric patients with recurrent and progressive solid tumors: A pediatric oncology group phase II study
-
DOI 10.1097/00043426-199807000-00006
-
Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998;20:315-18 (Pubitemid 28483337)
-
(1998)
Journal of Pediatric Hematology/Oncology
, vol.20
, Issue.4
, pp. 315-318
-
-
Nitschke, R.1
Parkhurst, J.2
Sullivan, J.3
Harris, M.B.4
Bernstein, M.5
Pratt, C.6
-
26
-
-
0035155499
-
Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study
-
Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2001;19:213-19 (Pubitemid 32063499)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.1
, pp. 213-219
-
-
Pappo, A.S.1
Lyden, E.2
Breneman, J.3
Wiener, E.4
Teot, L.5
Meza, J.6
Crist, W.7
Vietti, T.8
-
27
-
-
0035424844
-
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study
-
Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9 (Pubitemid 32730082)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.15
, pp. 3463-3469
-
-
Saylors III, R.L.1
Stine, K.C.2
Sullivan, J.3
Kepner, J.L.4
Wall, D.A.5
Bernstein, M.L.6
Harris, M.B.7
Hayashi, R.8
Vietti, T.J.9
-
28
-
-
70449698239
-
Vincristine actinomycin and cyclophosphamide compared with vincristine actinomycin and cyclophosphamide alternating with vincristine topotecan and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Childrens oncology group study d9803
-
Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 2009;27:5182-8
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5182-5188
-
-
Arndt, C.A.1
Stoner, J.A.2
Hawkins, D.S.3
-
29
-
-
31544451582
-
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma
-
DOI 10.1002/cncr.21629
-
Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006;106:703-7 (Pubitemid 43157635)
-
(2006)
Cancer
, vol.106
, Issue.3
, pp. 703-707
-
-
Bisogno, G.1
Riccardi, R.2
Ruggiero, A.3
Arcamone, G.4
Prete, A.5
Surico, G.6
Provenzi, M.7
Bertolini, P.8
Paolucci, P.9
Carli, M.10
-
30
-
-
33846951814
-
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The children's oncology group
-
DOI 10.1200/JCO.2006.07.1720
-
Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007;25:362-9 (Pubitemid 350002984)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.4
, pp. 362-369
-
-
Pappo, A.S.1
Lyden, E.2
Breitfeld, P.3
Donaldson, S.S.4
Wiener, E.5
Parham, D.6
Crews, K.R.7
Houghton, P.8
Meyer, W.H.9
-
31
-
-
62449214642
-
Randomized phase II window study of two schedules of irinotecan CPT-11 and vincristine VCR in rhabdomyosarcoma RMS at first relapse/disease progression
-
abstract 10013
-
Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J Clin Oncol 2008;26(15 Suppl):abstract 10013
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.15
-
-
Mascarenhas, L.1
Lyden, E.R.2
Breitfeld, P.P.3
-
32
-
-
33644841966
-
Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors
-
DOI 10.1200/JCO.2005.03.2847
-
Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-70 (Pubitemid 46630418)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.4
, pp. 563-570
-
-
Furman, W.L.1
Crews, K.R.2
Billups, C.3
Wu, J.4
Gajjar, A.J.5
Daw, N.C.6
Patrick, C.C.7
Rodriguez-Galindo, C.8
Stewart, C.F.9
Dome, J.S.10
Panetta, J.C.11
Houghton, P.J.12
Santana, V.M.13
-
33
-
-
66849095621
-
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
-
Ferraldeschi R, Minchell LJ, Roberts SA, et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics 2009;10:733-9
-
(2009)
Pharmacogenomics
, vol.10
, pp. 733-739
-
-
Ferraldeschi, R.1
Minchell, L.J.2
Roberts, S.A.3
-
34
-
-
76749168084
-
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
-
Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009;27:4599-604
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4599-4604
-
-
Furman, W.L.1
Navid, F.2
Daw, N.C.3
-
35
-
-
0035132902
-
6-methylguanine
-
Pourquier P, Waltman JL, Urasaki Y, et al. Topoisomerase I-mediated cytotoxicity of N-methyl-N¢-nitro-Nnitrosogunidine: trapping of topoisomerase I by the O6-methylguanidine. Cancer Res 2001;61:53-8 (Pubitemid 32095699)
-
(2001)
Cancer Research
, vol.61
, Issue.1
, pp. 53-58
-
-
Pourquier, P.1
Waltman, J.L.2
Urasaki, Y.3
Loktionova, N.A.4
Pegg, A.E.5
Nitiss, J.L.6
Pommier, Y.7
-
36
-
-
0033761232
-
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and misnatch repair phenotypes in xenograft models
-
Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and misnatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-18
-
(2000)
Clin. Cancer Res.
, vol.6
, pp. 4110-4118
-
-
Houghton, P.J.1
Stewart, C.F.2
Cheshire, P.J.3
-
37
-
-
0035008973
-
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V
-
DOI 10.1097/00043426-200105000-00008
-
Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20 (Pubitemid 32524925)
-
(2001)
Journal of Pediatric Hematology/Oncology
, vol.23
, Issue.4
, pp. 215-220
-
-
Raney, R.B.1
Anderson, J.R.2
Barr, F.G.3
Donaldson, S.S.4
Pappo, A.S.5
Qualman, S.J.6
Wiener, E.S.7
Maurer, H.M.8
Crist, W.M.9
-
38
-
-
44249090013
-
Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from united states and european cooperative groups
-
Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 2384-2389
-
-
Oberlin, O.1
Rey, A.2
Lyden, E.3
-
39
-
-
0031051491
-
Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue
-
Report of the German/Austrian Pediatric Bone Marrow Transplantation Group.
-
Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:227-31
-
(1997)
Bone Marrow Transplant
, vol.19
, pp. 227-231
-
-
Koscielniak, E.1
Klingebiel, T.H.2
Peters, C.3
-
40
-
-
0032868078
-
High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma
-
Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17:2796-803 (Pubitemid 29415237)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.9
, pp. 2796-2803
-
-
Carli, M.1
Colombatti, R.2
Oberlin, O.3
Stevens, M.4
Masiero, L.5
Frascella, E.6
Koscielniak, E.7
Treuner, J.8
Pinkerton, C.R.9
-
41
-
-
0034918470
-
Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma
-
DOI 10.1097/00043426-200106000-00007
-
Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001;23:272-6 (Pubitemid 32662033)
-
(2001)
Journal of Pediatric Hematology/Oncology
, vol.23
, Issue.5
, pp. 272-276
-
-
Weigel, B.J.1
Breitfeld, P.P.2
Hawkins, D.3
Crist, W.M.4
Baker, K.S.5
-
42
-
-
70350602712
-
Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma
-
Bisogno G, Ferrari A, Prete A, et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer 2009;45:3035-41
-
(2009)
Eur. J. Cancer
, vol.45
, pp. 3035-3041
-
-
Bisogno, G.1
Ferrari, A.2
Prete, A.3
-
44
-
-
0033977253
-
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children
-
PII S0959804999002361
-
Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87-94 (Pubitemid 30035349)
-
(2000)
European Journal of Cancer
, vol.36
, Issue.1
, pp. 87-94
-
-
Womer, R.B.1
Daller, R.T.2
Fenton, J.G.3
Miser, J.S.4
-
45
-
-
79960454992
-
Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma RMS
-
Early results from Childrens Oncology Group (COG) ARST0431: abstract 9503
-
Weigel B, Lyden E, Anderson JR, et al.; Early results from Children's Oncology Group (COG) ARST0431. Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). J Clin Oncol 2010;28(15 Suppl):abstract 9503
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15
-
-
Weigel, B.1
Lyden, E.2
Anderson, J.R.3
-
46
-
-
0037096950
-
Vinorelbine in previously treated advanced childhood sarcomas: Evidence of activity in rhadbomyosarcoma
-
DOI 10.1002/cncr.10600
-
Casanova M, Ferrari A, Spreafico F, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002;94:3263-8 (Pubitemid 34670510)
-
(2002)
Cancer
, vol.94
, Issue.12
, pp. 3263-3268
-
-
Casanova, M.1
Ferrari, A.2
Spreafico, F.3
Terenziani, M.4
Massimino, M.5
Luksch, R.6
Cefalo, G.7
Polastri, D.8
Marcon, I.9
Bellani, F.F.10
-
47
-
-
4844220366
-
Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: Pilot study for the upcoming European rhabdomyosarcoma protocol
-
DOI 10.1002/cncr.20544
-
Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004;101:1664-71 (Pubitemid 39318915)
-
(2004)
Cancer
, vol.101
, Issue.7
, pp. 1664-1671
-
-
Casanova, M.1
Ferrari, A.2
Bisogno, G.3
Merks, J.H.M.4
De Salvo, G.L.5
Meazza, C.6
Tettoni, K.7
Provenzi, M.8
Mazzarino, I.9
Carli, M.10
-
48
-
-
40449142495
-
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial
-
DOI 10.1002/pbc.21494
-
Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 2008;50:739-45 (Pubitemid 351354776)
-
(2008)
Pediatric Blood and Cancer
, vol.50
, Issue.4
, pp. 739-745
-
-
Klingebiel, T.1
Boos, J.2
Beske, F.3
Hallmen, E.4
Int-Veen, C.5
Dantonello, T.6
Treuner, J.7
Gadner, H.8
Marky, I.9
Kazanowska, B.10
Koscielniak, E.11
-
49
-
-
77953019735
-
Targets for cancer therapy in childhood sarcomas
-
10.1016/j.ctrv.2010.02.007
-
Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010, doi:10.1016/j.ctrv.2010.02.007
-
(2010)
Cancer Treat. Rev.
-
-
Wachtel, M.1
Schafer, B.W.2
-
50
-
-
77953026387
-
The role of the innovative therapies for children with cancer ITCC European consortium
-
10.1016/j.ctrv.2010.02.008
-
Zwaan CM, Kearns P, Caron H, et al. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. Cancer Treat Rev 2010, doi:10.1016/j.ctrv.2010.02.008
-
(2010)
Cancer Treat. Rev.
-
-
Zwaan, C.M.1
Kearns, P.2
Caron, H.3
-
51
-
-
0036896670
-
Testing of new agents in childhood cancer preclinical models: Meeting summary
-
Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002;8:3646-57 (Pubitemid 35424754)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.12
, pp. 3646-3657
-
-
Houghton, P.J.1
Adamson, P.C.2
Blaney, S.3
Fine, H.A.4
Gorlick, R.5
Haber, M.6
Helman, L.7
Hirschfeld, S.8
Hollingshead, M.G.9
Israel, M.A.10
Lock, R.B.11
Maris, J.M.12
Merlino, G.13
Patterson, W.14
Reynolds, C.P.15
Shannon, K.16
Yu, A.17
Yu, J.18
Smith, M.A.19
-
52
-
-
0035728324
-
Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein
-
DOI 10.1054/ghir.2001.0244
-
Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97 (Pubitemid 34257726)
-
(2001)
Growth Hormone and IGF Research
, vol.11
, Issue.5
, pp. 289-297
-
-
Ayalon, D.1
Glaser, T.2
Werner, H.3
-
53
-
-
0028115727
-
Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells
-
Minniti CO, Tsokos M, Newton W Jr, Helman LJ. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994;101:198-203 (Pubitemid 24061448)
-
(1994)
American Journal of Clinical Pathology
, vol.101
, Issue.2
, pp. 198-203
-
-
Minniti, C.P.1
Tsokos, M.2
Newton Jr., W.A.3
Helman, L.J.4
-
54
-
-
0028053410
-
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2
-
Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994;54:5531-4
-
(1994)
Cancer Res..
, vol.54
, pp. 5531-5534
-
-
Kalebic, T.1
Tsokos, M.2
Helman, L.J.3
-
55
-
-
0032513524
-
Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R
-
DOI 10.100 2/(SICI)109 7-0215(199804 13)76:2<223:: AID-IJC9>3.0.CO;2-Z
-
Kalebic T, Blaskesley V, Slade C, et al. Expression of a kinase-deficient IGF-1-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing wild type IGF-1-R. Int J Cancer 1998;76:223-7 (Pubitemid 28180376)
-
(1998)
International Journal of Cancer
, vol.76
, Issue.2
, pp. 223-227
-
-
Kalebic, T.1
Blakesley, V.2
Slade, C.3
Plasschaert, S.4
Leroith, D.5
Lee Helman, J.6
-
56
-
-
42349083307
-
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
-
DOI 10.1002/pbc.21450
-
Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-7 (Pubitemid 351555543)
-
(2008)
Pediatric Blood and Cancer
, vol.50
, Issue.6
, pp. 1190-1197
-
-
Anders Kolb, E.1
Gorlick, R.2
Houghton, P.J.3
Morton, C.L.4
Lock, R.5
Carol, H.6
Patrick Reynolds, C.7
Maris, J.M.8
Keir, S.T.9
Billups, C.A.10
Smith, M.A.11
-
57
-
-
20944447905
-
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
-
DOI 10.1158/0008-5472.CAN-04-3192
-
Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-1 receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76 (Pubitemid 40616368)
-
(2005)
Cancer Research
, vol.65
, Issue.9
, pp. 3868-3876
-
-
Scotlandi, K.1
Manara, M.C.2
Nicoletti, G.3
Lollini, P.-L.4
Lukas, S.5
Benini, S.6
Croci, S.7
Perdichizzi, S.8
Zambelli, D.9
Serra, M.10
Garcia-Echeverria, C.11
Hofmann, F.12
Picci, P.13
-
58
-
-
54249157471
-
Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
-
Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-48
-
(2008)
Cancer Res..
, vol.68
, pp. 8039-8048
-
-
Cao, L.1
Yu, Y.2
Darko, I.3
-
59
-
-
33646404053
-
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma
-
Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9
-
(2006)
Cancer Res.
, vol.66
, pp. 4742-4749
-
-
Taulli, R.1
Scuoppo, C.2
Bersani, F.3
-
60
-
-
36049018288
-
Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: Correlation with overall survival in 105 patients
-
DOI 10.1002/cncr.23038
-
Armistead PM, Salganick J, Roh JS, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007;110:2293-303 (Pubitemid 350100752)
-
(2007)
Cancer
, vol.110
, Issue.10
, pp. 2293-2303
-
-
Armistead, P.M.1
Salganick, J.2
Roh, J.S.3
Steinert, D.M.4
Patel, S.5
Munsell, M.6
El-Naggar, A.K.7
Benjamin, R.S.8
Zhang, W.9
Trent, J.C.10
-
61
-
-
55249083566
-
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma
-
Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-60
-
(2008)
Oncogene
, vol.27
, pp. 6550-6560
-
-
Taniguchi, E.1
Nishijo, K.2
McCleish, A.T.3
-
62
-
-
0036196163
-
Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma
-
DOI 10.1006/geno.2002.6703
-
Barber T, Barber M, Tomescu O, et al. Identification of target genes regulated by PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 2002;79:278-84 (Pubitemid 34211935)
-
(2002)
Genomics
, vol.79
, Issue.3
, pp. 278-284
-
-
Barber, T.D.1
Barber, M.C.2
Tomescu, O.3
Barr, F.G.4
Ruben, S.5
Friedman, T.B.6
-
63
-
-
33644817251
-
The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts
-
Wang W, Slevin M, Kumar S, Kumar P. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int J Oncol 2005;27:1087-96
-
(2005)
Int. J. Oncol.
, vol.27
, pp. 1087-1096
-
-
Wang, W.1
Slevin, M.2
Kumar, S.3
Kumar, P.4
-
64
-
-
24344448690
-
Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines
-
Onisto M, Slongo M, Gregnanin L, et al. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005;27:791-98
-
(2005)
Int. J. Oncol.
, vol.27
, pp. 791-798
-
-
Onisto, M.1
Slongo, M.2
Gregnanin, L.3
-
65
-
-
28544444282
-
Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid
-
DOI 10.1038/sj.onc.1208939
-
Gee MF, Tsuchida R, Eichler-Jonsson C, et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005;24:8025-37 (Pubitemid 41746746)
-
(2005)
Oncogene
, vol.24
, Issue.54
, pp. 8025-8037
-
-
Gee, M.F.W.1
Tsuchida, R.2
Eichler-Jonsson, C.3
Das, B.4
Baruchel, S.5
Malkin, D.6
-
66
-
-
84875833298
-
A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma RMS and non-rhabdomyosarcoma soft tissue sarcoma NRSTS
-
abstract TPS330
-
Chisholm JC, Casanova M, Geoerger B, et al. A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). J Clin Oncol 2010;28(15 Suppl):abstract TPS330
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.15
-
-
Chisholm, J.C.1
Casanova, M.2
Geoerger, B.3
-
67
-
-
34248216623
-
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
-
DOI 10.1158/0008-5472.CAN-06-1344
-
Petricoin EF III, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.Cancer Res 2007;67:3431-40 (Pubitemid 46724884)
-
(2007)
Cancer Research
, vol.67
, Issue.7
, pp. 3431-3440
-
-
Petricoin III, E.F.1
Espina, V.2
Araujo, R.P.3
Midura, B.4
Yeung, C.5
Wan, X.6
Eichler, G.S.7
Johann Jr., D.J.8
Qualman, S.9
Tsokos, M.10
Krishnan, K.11
Helman, L.J.12
Liotta, L.A.13
-
68
-
-
34548427415
-
The biology behind mTOR inhibition in sarcoma
-
DOI 10.1634/theoncologist.12-8-1007
-
Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma.Oncologist 2007;12:1007-18 (Pubitemid 47359144)
-
(2007)
Oncologist
, vol.12
, Issue.8
, pp. 1007-1018
-
-
Wan, X.1
Helman, L.J.2
-
69
-
-
40449091406
-
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
-
DOI 10.1002/pbc.21296
-
Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008;50:799-805 (Pubitemid 351354788)
-
(2008)
Pediatric Blood and Cancer
, vol.50
, Issue.4
, pp. 799-805
-
-
Houghton, P.J.1
Morton, C.L.2
Kolb, E.A.3
Gorlick, R.4
Lock, R.5
Carol, H.6
Reynolds, C.P.7
Maris, J.M.8
Keir, S.T.9
Billups, C.A.10
Smith, M.A.11
-
70
-
-
70350227313
-
The Insulin-like growth factor-1 receptor-targeting antibody CP-751 871 suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma
-
Kurmasheva R, Dudkin L, Billuos C, et al. The Insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
-
(2009)
Cancer Res
, vol.69
, pp. 7662-7671
-
-
Kurmasheva, R.1
Dudkin, L.2
Billuos, C.3
-
71
-
-
47249152832
-
Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas
-
Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas. Expert Rev Anticancer Ther 2008;8:929-38
-
(2008)
Expert Rev. Anticancer Ther.
, vol.8
, pp. 929-938
-
-
Ferrari, A.1
-
72
-
-
33644667931
-
Malignant peripheral nerve sheath tumors in pediatric age: A report from the italian and german soft tissue sarcoma cooperative group
-
Carli M, Ferrari A, Mattke A, et al. Malignant peripheral nerve sheath tumors in pediatric age: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005;23:8422-30
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 8422-8430
-
-
Carli, M.1
Ferrari, A.2
Mattke, A.3
-
73
-
-
31544480125
-
Epithelioid sarcoma in children and adolescents: A report from the Italian Soft Tissue Sarcoma Committee
-
DOI 10.1002/cncr.21630
-
Casanova M, Ferrari A, Collini P, et al. Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer 2006;106:708-17 (Pubitemid 43157636)
-
(2006)
Cancer
, vol.106
, Issue.3
, pp. 708-717
-
-
Casanova, M.1
Ferrari, A.2
Collini, P.3
Bisogno, G.4
Alaggio, R.5
Cecchetto, G.6
Gronchi, A.7
Meazza, C.8
Garaventa, A.9
Di Cataldo, A.10
Carli, M.11
-
74
-
-
74949095728
-
Infantile fibrosarcoma: Place of chemotherapy and treatment proposals based on the European experience
-
Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: place of chemotherapy and treatment proposals based on the European experience. J Clin Oncol 2010;28:318-23
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 318-323
-
-
Orbach, D.1
Rey, A.2
Cecchetto, G.3
-
75
-
-
9244234991
-
Desmoplastic small round-cell tumor: Prolonged progression-free survival with aggressive multimodality therapy
-
Kushner BH, La Quaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996;14:1526-31 (Pubitemid 26134209)
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.5
, pp. 1526-1531
-
-
Kushner, B.H.1
LaQuaglia, M.P.2
Wollner, N.3
Meyers, P.A.4
Lindsley, K.L.5
Ghavimi, F.6
Merchant, T.E.7
Boulad, F.8
Cheung, N.-K.V.9
Bonilla, M.A.10
Crouch, G.11
Kelleher Jr., J.F.12
Steinherz, P.G.13
Gerald, W.L.14
-
76
-
-
0034093381
-
Desmoplastic small round cell tumor in children and adolescents
-
DOI 10.100 2/(SICI)1096-9 11X(200005)34:5<33 8::AID-MPO4>3.0.CO;2-0
-
Bisogno G, Roganovich J, Sotti G, et al. Desmoplastic small round cell tumor in children and adolescents. Med Pediatr Oncol 2000;34:338-42 (Pubitemid 30230608)
-
(2000)
Medical and Pediatric Oncology
, vol.34
, Issue.5
, pp. 338-342
-
-
Bisogno, G.1
Roganovich, J.2
Sotti, G.3
Ninfo, V.4
Di Montezemolo, L.C.5
Donfrancesco, A.6
Mascarin, M.7
Carli, M.8
-
77
-
-
36348969467
-
Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma
-
DOI 10.1016/j.ejca.2007.09.012, PII S0959804907007411
-
Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in pediatric age: a nomogram-based prognostic comparison with adult sarcomas. Eur J Cancer 2007;43:2691-7 (Pubitemid 350151845)
-
(2007)
European Journal of Cancer
, vol.43
, Issue.18
, pp. 2691-2697
-
-
Ferrari, A.1
Miceli, R.2
Casanova, M.3
Gronchi, A.4
Collini, P.5
Meazza, C.6
Zaffignani, E.7
Massimino, M.8
Spreafico, F.9
Mariani, L.10
-
78
-
-
68149158316
-
Comparing children and adults with synovial sarcoma in the surveillance epidemiology and end results program 1983 to 2005: An analysis of 1268 patients
-
Sultan I, Rodriguez-Galindo IC, Saab R, et al. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009;115:3537-47
-
(2009)
Cancer
, vol.115
, pp. 3537-3547
-
-
Sultan, I.1
Rodriguez-Galindo, I.C.2
Saab, R.3
-
79
-
-
44449110447
-
Synovial sarcoma of children and adolescents: The prognostic role of axial sites
-
Ferrari A, Bisogno G, Alaggio R, et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 2008;44:1202-9
-
(2008)
Eur. J. Cancer
, vol.44
, pp. 1202-1209
-
-
Ferrari, A.1
Bisogno, G.2
Alaggio, R.3
-
80
-
-
0032953485
-
Synovial sarcoma: Report of a series of 25 consecutive children from a single institution
-
DOI 10.10 02/(SICI)10 96-911X(199 901)32:1<32::A ID-MPO7>3.0.CO;2-1
-
Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol 1999;32:32-7 (Pubitemid 29029336)
-
(1999)
Medical and Pediatric Oncology
, vol.32
, Issue.1
, pp. 32-37
-
-
Ferrari, A.1
Casanova, M.2
Massimino, M.3
Luksch, R.4
Cefalo, G.5
Lombardi, F.6
Galimberti, S.7
Riganti, G.8
Fossati-Bellani, F.9
-
81
-
-
0038518563
-
Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome
-
DOI 10.1200/JCO.2003.07.008
-
Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003;21:1602-11 (Pubitemid 46594115)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.8
, pp. 1602-1611
-
-
Okcu, M.F.1
Munsell, M.2
Treuner, J.3
Mattke, A.4
Pappo, A.5
Cain, A.6
Ferrari, A.7
Casanova, M.8
Ozkan, A.9
Raney, B.10
-
82
-
-
0028053507
-
Synovial sarcoma in children and adolescents: The St Jude Children's Research Hospital experience
-
Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: the St. Jude Children's Research Hospital experience. J Clin Oncol 1994;12:2360-6 (Pubitemid 24346708)
-
(1994)
Journal of Clinical Oncology
, vol.12
, Issue.11
, pp. 2360-2366
-
-
Pappo, A.S.1
Fontanesi, J.2
Luo, X.3
Rao, B.N.4
Parham, D.M.5
Hurwitz, C.6
Avery, L.7
Pratt, C.B.8
-
83
-
-
0027225473
-
Synovial sarcoma of childhood and adolescence: Report of the German CWS- 81 study
-
DOI 10.10 02/1097-0142(1993 0601)71:11<36 47::AID-CNCR 2820711129>3.0.CO;2-U
-
Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence: report of the German CWS-81 study. Cancer 1993;71:3647-55 (Pubitemid 23152678)
-
(1993)
Cancer
, vol.71
, Issue.11
, pp. 3647-3655
-
-
Ladenstein, R.1
Treuner, J.2
Koscielniak, E.3
D'Oleire, F.4
Keim, M.5
Gadner, H.6
Jurgens, H.7
Niethammer, D.8
Ritter, J.9
Schmidt, D.10
-
84
-
-
77953243719
-
Synovial sarcoma in childhood and adolescence: A retrospective series of 77 patients registered by the childrens cancer and leukaemia group between 1991 and 2006
-
published online 8 Mar 2010.1002/pbc.22453
-
Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer 2010: published online 8 Mar 2010, doi 10.1002/pbc.22453
-
(2010)
Pediatr Blood Cancer
-
-
Brennan, B.1
Stevens, M.2
Kelsey, A.3
Stiller, C.A.4
-
85
-
-
3242785674
-
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
-
DOI 10.1002/cncr.20386
-
Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004;101:627-34 (Pubitemid 38970615)
-
(2004)
Cancer
, vol.101
, Issue.3
, pp. 627-634
-
-
Ferrari, A.1
Gronchi, A.2
Casanova, M.3
Meazza, C.4
Gandola, L.5
Collini, P.6
Lozza, L.7
Bertulli, R.8
Olmi, P.9
Casali, P.G.10
-
86
-
-
0034110979
-
Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity
-
Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000;18:2087-94 (Pubitemid 30324362)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.10
, pp. 2087-2094
-
-
Lewis, J.J.1
Antonescu, C.R.2
Leung, D.H.Y.3
Blumberg, D.4
Healey, J.H.5
Woodruff, J.M.6
Brennan, M.F.7
-
87
-
-
0035863551
-
Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients
-
Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001;19:525-34 (Pubitemid 32112867)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.2
, pp. 525-534
-
-
Trassard, M.1
Le Doussal, V.2
Hacene, K.3
Terrier, P.4
Ranchere, D.5
Guillou, L.6
Fiche, M.7
Collin, F.8
Vilain, M.-O.9
Bertrand, G.10
Jacquemier, J.11
Sastre-Garau, X.12
Bui, N.B.13
Bonichon, F.14
Coindre, J.-M.15
-
88
-
-
0027280571
-
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas
-
Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85 (Pubitemid 23199130)
-
(1993)
Journal of Clinical Oncology
, vol.11
, Issue.7
, pp. 1276-1285
-
-
Antman, K.1
Crowley, J.2
Balcerzak, S.P.3
Rivkin, S.E.4
Weiss, G.R.5
Elias, A.6
Natale, R.B.7
Cooper, R.M.8
Barlogie, B.9
Trump, D.L.10
Doroshow, J.H.11
Aisner, J.12
Pugh, R.P.13
Weiss, R.B.14
Cooper, B.A.15
Clamond, G.H.16
Baker, L.H.17
-
89
-
-
0028334634
-
Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - Reduced local recurrence but no improvement in survival: A study on the European organization for research and treatment of cancer soft tissue sarcoma and bone sarcoma group
-
Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study on the European Organization for Research and Treatment of Cancer Soft Tissue Sarcoma and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-49
-
(1994)
J. Clin. Oncol.
, vol.12
, pp. 1137-1149
-
-
Bramwell, V.1
Rouesse, J.2
Steward, W.3
-
90
-
-
0029005580
-
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group
-
Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45
-
(1995)
J. Clin. Oncol.
, vol.13
, pp. 1537-1545
-
-
Santoro, A.1
Tursz, T.2
Mouridsen, H.3
-
91
-
-
71949083033
-
Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma
-
Ferrari A. Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 2009;9:1541-3
-
(2009)
Expert Rev. Anticancer Ther.
, vol.9
, pp. 1541-1543
-
-
Ferrari, A.1
-
92
-
-
28844499178
-
Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative groups: Discussion on the role of adjuvant therapies
-
DOI 10.1002/pbc.20502
-
Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr Blood Cancer 2006;46:11-7 (Pubitemid 41779312)
-
(2006)
Pediatric Blood and Cancer
, vol.46
, Issue.1
, pp. 11-17
-
-
Brecht, I.B.1
Ferrari, A.2
Int-Veen, C.3
Schuck, A.4
Mattke, A.C.5
Casanova, M.6
Bisogno, G.7
Carli, M.8
Koscielniak, E.9
Treuner, J.10
-
93
-
-
34548413977
-
Combined modalities approach for localized adult extremity soft-tissue sarcoma
-
DOI 10.1586/14737140.7.8.1135
-
Gronchi A, Olmi P, Casali PG. Combined modalities approach for localised adult extremity soft-tissue sarcoma. Expert Rev Anticancer Ther 2007;7:1135-44 (Pubitemid 47365006)
-
(2007)
Expert Review of Anticancer Therapy
, vol.7
, Issue.8
, pp. 1135-1144
-
-
Gronchi, A.1
Olmi, P.2
Casali, P.G.3
-
94
-
-
0035281643
-
Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care?
-
Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol 2001;19:1235-7 (Pubitemid 32202525)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.5
, pp. 1235-1237
-
-
Bramwell, V.H.C.1
-
95
-
-
0031566814
-
Sarcoma meta-analysis collaboration adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: Meta-analysis of individual data
-
Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54
-
(1997)
Lancet
, vol.350
, pp. 1647-1654
-
-
-
96
-
-
0036682012
-
Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma
-
DOI 10.1200/JCO.2002.06.066
-
Spunt SL, Ashley Hill D, Motosue AM, et al. Clinical features and outcome of initially unresected nonmetastatic pediatric non-rhabdomyosarcoma soft tissue sarcoma. J Clin Oncol 2002;20:3225-35 (Pubitemid 34831519)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.15
, pp. 3225-3235
-
-
Spunt, S.L.1
Hill, D.A.2
Motosue, A.M.3
Billups, C.A.4
Cain, A.M.5
Rao, B.N.6
Pratt, C.B.7
Merchant, T.E.8
Pappo, A.S.9
-
97
-
-
17944395368
-
Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A pediatric oncology group study
-
DOI 10.1002/(SI CI)1096-911 X(199804)30:4<20 1::AID-MPO1>3.0.CO;2-K
-
Pratt CB, Maurer HM, Gieser P, et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group Study. Med Pediatr Oncol 1998;30:201-9 (Pubitemid 28082444)
-
(1998)
Medical and Pediatric Oncology
, vol.30
, Issue.4
, pp. 201-209
-
-
Pratt, C.B.1
Maurer, H.M.2
Gieser, P.3
Salzberg, A.4
Rao, B.N.5
Parham, D.6
Thomas, P.R.M.7
Marcus, R.B.8
Cantor, A.9
Pick, T.10
Green, D.11
Neff, J.12
Jenkins, J.J.13
-
98
-
-
23044441741
-
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: A pediatric oncology group study
-
DOI 10.1200/JCO.2005.03.209
-
Pappo AS, Devidas M, Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23:4031-8 (Pubitemid 46211307)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4031-4038
-
-
Pappo, A.S.1
Devidas, M.2
Jenkins, J.3
Rao, B.4
Marcus, R.5
Thomas, P.6
Gebhardt, M.7
Pratt, C.8
Grier, H.E.9
-
99
-
-
22244438918
-
The role of adjuvant chemotherapy in children and adolescents with surgically resected, high-risk adult-type soft tissue sarcomas
-
DOI 10.1002/pbc.20376
-
Ferrari A, Brecht IB, Koscielniak E, et al. The role of adjuvant chemotherapy in surgically-resected adult-type soft tissue sarcomas of children and adolescents. Pediatr Blood Cancer 2005;45:128-34 (Pubitemid 40993577)
-
(2005)
Pediatric Blood and Cancer
, vol.45
, Issue.2
, pp. 128-134
-
-
Ferrari, A.1
Brecht, I.B.2
Koscielniak, E.3
Casanova, M.4
Scagnellato, A.5
Bisogno, G.6
Alaggio, R.7
Cecchetto, G.8
Catania, S.9
Meazza, C.10
Int-Veen, C.11
Kirsch, S.12
Dantonello, T.13
Carli, M.14
Treuner, J.15
-
100
-
-
0028856442
-
The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view
-
Verweij J, Mouridsen HT, Nielssen OS, et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201
-
(1995)
Crit. Rev. Oncol. Hematol.
, vol.20
, pp. 193-201
-
-
Verweij, J.1
Mouridsen, H.T.2
Nielssen, O.S.3
-
101
-
-
0035282058
-
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the italian randomized cooperative trial
-
Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-47 (Pubitemid 32202526)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.5
, pp. 1238-1247
-
-
Frustaci, S.1
Gherlinzoni, F.2
De Paoli, A.3
Bonetti, M.4
Azzarelli, A.5
Comandone, A.6
Olmi, P.7
Buonadonna, A.8
Pignatti, G.9
Barbieri, E.10
Apice, G.11
Zmerly, H.12
Serraino, D.13
Picci, P.14
-
102
-
-
0032927813
-
Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study
-
Pratt CB, Pappo AS, Gieser P, et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 1999;17:1219-26 (Pubitemid 29162947)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.4
, pp. 1219-1226
-
-
Pratt, C.B.1
Pappo, A.S.2
Gieser, P.3
Jenkins, J.J.4
Salzberg, A.5
Neff, J.6
Rao, B.7
Green, D.8
Thomas, P.9
Marcus, R.10
Parham, D.11
Maurer, H.12
-
103
-
-
0033571557
-
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
-
Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-7
-
(1999)
Cancer
, vol.86
, pp. 2034-2037
-
-
Fata, F.1
O'Reilly, E.2
Ilson, D.3
-
104
-
-
55949086834
-
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX study
-
Penel N, Bui B, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-74
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5269-5274
-
-
Penel, N.1
Bui, B.2
Bay, J.O.3
-
105
-
-
0037096747
-
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial
-
DOI 10.1200/JCO.2002.11.050
-
Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31 (Pubitemid 34651511)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.12
, pp. 2824-2831
-
-
Hensley, M.L.1
Maki, R.2
Venkatraman, E.3
Geller, G.4
Lovegren, M.5
Aghajanian, C.6
Sabbatini, P.7
Tong, W.8
Barakat, R.9
Spriggs, D.R.10
-
106
-
-
34447572873
-
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
-
DOI 10.1200/JCO.2006.10.4117
-
Maki R, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002. J Clin Oncol 2007;5:2755-63 (Pubitemid 47123184)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.19
, pp. 2755-2763
-
-
Maki, R.G.1
Wathen, J.K.2
Patel, S.R.3
Priebat, D.A.4
Okuno, S.H.5
Samuels, B.6
Fanucchi, M.7
Harmon, D.C.8
Schuetze, S.M.9
Reinke, D.10
Thall, P.F.11
Benjamin, R.S.12
Baker, L.H.13
Hensley, M.L.14
-
107
-
-
34347214071
-
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study
-
DOI 10.1016/S1470-2045(07)70175-4, PII S1470204507701754
-
Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602 (Pubitemid 46995623)
-
(2007)
Lancet Oncology
, vol.8
, Issue.7
, pp. 595-602
-
-
Grosso, F.1
Jones, R.L.2
Demetri, G.D.3
Judson, I.R.4
Blay, J.-Y.5
Le Cesne, A.6
Sanfilippo, R.7
Casieri, P.8
Collini, P.9
Dileo, P.10
Spreafico, C.11
Stacchiotti, S.12
Tamborini, E.13
Tercero, J.C.14
Jimeno, J.15
D'Incalci, M.16
Gronchi, A.17
Fletcher, J.A.18
Pilotti, S.19
Casali, P.G.20
more..
-
108
-
-
38749093970
-
Trabectedin in metastatic ewings family tumors patients progressing after standard chemotherapy
-
abstract 1004
-
Dileo P, Grosso F, Casanova M, et al. Trabectedin in metastatic Ewing's family tumors patients progressing after standard chemotherapy. J Clin Oncol 2007;25(18S):abstract 10040
-
(2007)
J. Clin. Oncol.
, vol.25
-
-
Dileo, P.1
Grosso, F.2
Casanova, M.3
-
109
-
-
69449106265
-
Trabectedin in myxoid liposarcomas MLS: A long-term analysis of a single-institution series
-
Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20:1439-44
-
(2009)
Ann. Oncol.
, vol.20
, pp. 1439-1444
-
-
Grosso, F.1
Sanfilippo, R.2
Virdis, E.3
-
110
-
-
14144256775
-
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225
-
DOI 10.1200/JCO.2005.07.088
-
McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2003;23:866-73 (Pubitemid 46224187)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 866-873
-
-
McArthur, G.A.1
Demetri, G.D.2
Van Oosterom, A.3
Heinrich, M.C.4
Debiec-Rychter, M.5
Corless, C.L.6
Nikolova, Z.7
Dimitrijevic, S.8
Fletcher, J.A.9
-
111
-
-
20844459809
-
Imatinib mesylate in chordoma
-
DOI 10.1002/cncr.20618
-
Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004;101:2086-97 (Pubitemid 39425386)
-
(2004)
Cancer
, vol.101
, Issue.9
, pp. 2086-2097
-
-
Casali, P.G.1
Messina, A.2
Stacchiotti, S.3
Tamborini, E.4
Crippa, F.5
Gronchi, A.6
Orlandi, R.7
Ripamonti, C.8
Spreafico, C.9
Bertieri, R.10
Bertulli, R.11
Colecchia, M.12
Fumagalli, E.13
Greco, A.14
Grosso, F.15
Olmi, P.16
Pierotti, M.A.17
Pilotti, S.18
-
112
-
-
33644977853
-
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
-
DOI 10.1200/JCO.2005.04.0717
-
Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-203 (Pubitemid 46638818)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.7
, pp. 1195-1203
-
-
Heinrich, M.C.1
McArthur, G.A.2
Demetri, G.D.3
Joensuu, H.4
Bono, P.5
Herrmann, R.6
Hirte, H.7
Cresta, S.8
Koslin, D.B.9
Corless, C.L.10
Dirnhofer, S.11
Van Oosterom, A.T.12
Nikolova, Z.13
Dimitrijevic, S.14
Fletcher, J.A.15
-
113
-
-
67650337802
-
Pazopanib a multikinase angiogenesis inhibitor in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organization for research and treatment of cancer - Soft tissue and bone sarcoma group eortc study 62043
-
SleiJfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 3126-3132
-
-
SleiJfer, S.1
Ray-Coquard, I.2
Papai, Z.3
-
114
-
-
37149033966
-
Survival results with AP23573, a novel mTOR inhibitor in patients with advanced soft tissue sarcomas: Update of a phase II trial
-
abstract 1007
-
Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue sarcomas: update of a phase II trial. J Clin Oncol 2007;25(18S):abstract 10076
-
(2007)
J. Clin. Oncol.
, vol.25
-
-
Chawla, S.P.1
Tolcher, A.W.2
Staddon, A.P.3
-
115
-
-
51449089221
-
Deferolimus trial 106 - A phase I trial evaluating 7 regimens of oral deforolimus AP23573 MK-8669
-
abstract 3509
-
Mita MM, Britten CD, Poplin E, et al. Deferolimus trial 106 - a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). J Clin Oncol 2008;26(15S):abstract 3509
-
(2008)
J. Clin. Oncol.
, vol.26
-
-
Mita, M.M.1
Britten, C.D.2
Poplin, E.3
-
116
-
-
79951628241
-
Updating progress in sarcoma therapy with mTOR inhibitors
-
Epub ahead of print]
-
Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2010. [Epub ahead of print]
-
(2010)
Ann. Oncol.
-
-
Blay, J.Y.1
-
117
-
-
78650050500
-
Activity of eribulin mesylate E7389 in patients with soft tissue sarcoma STS: Phase II studies of the European organisation for research and treatment of cancer soft tissue and bone sarcoma group eortc 62052
-
abstract 1003
-
Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). J Clin Oncol 2010;28(15S):abstract 10031
-
(2010)
J. Clin. Oncol.
, vol.28
-
-
Schoffski, P.1
Ray-Coquard, I.L.2
Cioffi, A.3
-
118
-
-
75449117196
-
A SARC global collaborative phase II trial of R1507 a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor IGF1R in patients with recurrent or refractory sarcomas
-
abstract 1050
-
Patel S, Pappo A, Crowley J, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J Clin Oncol 2010;27(15S):abstract 10503
-
(2010)
J. Clin. Oncol.
, vol.27
-
-
Patel, S.1
Pappo, A.2
Crowley, J.3
|